<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../k34gmbu8.html">Pocket Medicine
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0015.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0017.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h122" class="calibre7"></a><a id="page_11-1" class="calibre7"></a><a href="part0002.html#rh136" class="calibre7">ICU MEDICATIONS</a></h2>
<p class="imagef"><img src="../images/00140.jpeg" alt="" class="calibre2"/></p>
<p class="image"><a id="page_11-2" class="calibre1"></a><img src="../images/00141.jpeg" alt="" class="calibre2"/></p>
<p class="capf"><b class="calibre4">Figure 11-1</b> ACLS pulmonary edema, hypotension or shock algorithm</p>
<p class="center"><img src="../images/00142.jpeg" alt="" class="calibre2"/></p>
<p class="fn">(Adapted from ACLS 2005 Guidelines)</p>
<h2 class="ct"><a id="h123" class="calibre7"></a><a id="page_11-3" class="calibre7"></a><a href="part0002.html#rh137" class="calibre7">ANTIBIOTICS</a></h2>
<p class="cst"><i class="calibre3">The following tables of spectra of activity for different antibiotics are generalizations. Sensitivity data at your own institution should be used to guide therapy.</i></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre17"/>
<col class="calibre17"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc">Penicillins</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Generation</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Properties</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Spectrum</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Natural</b><br class="calibre6"/>(eg, penicillin)</p></td>
<td class="bg0-br"><p class="tab">Some GPC, GPR, GNC, many anaerobes (not <i class="calibre3">Bacteroides</i>)</p></td>
<td class="bg0-b"><p class="tab">Group A strep, Enterococci, <i class="calibre3">Listeria, Pasteurella, Actinomyces</i>, Syphilis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Anti-staph</b><br class="calibre6"/>(eg, nafcillin)</p></td>
<td class="bg0-br"><p class="tab">Active vs. PCNase-producing Staph Little activity vs. Gram ⊖</p></td>
<td class="bg0-b"><p class="tab">Staphylococci (except MRSA) Streptococci</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Amino</b><br class="calibre6"/>(eg, ampicillin)</p></td>
<td class="bg0-br"><p class="tab">Penetrate porin channel of Gram ⊖ <br class="calibre6"/>Not stable against PCNases</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">E. coli, Proteus, Listeria, H. influenzae Salmonella, Shigella, Enterococci</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Extended</b><br class="calibre6"/>(eg, piperacillin)</p></td>
<td class="bg0-br"><p class="tab">Penetrate porin channel of Gram ⊖ <br class="calibre6"/>More resistant to PCNases</p></td>
<td class="bg0-b"><p class="tab">Most GNR incl. <i class="calibre3">Enterobacter, Pseudomonas, Serratia</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Carbapenems</b><br class="calibre6"/>(eg, imipenem)</p></td>
<td class="bg0-br"><p class="tab">Resistant to most β-lactamases</p></td>
<td class="bg0-b"><p class="tab">Most Gram ⊕ &amp; ⊖, incl. anaerobes; <i class="calibre3">not</i> MRSA or VRE</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Monobactams</b><br class="calibre6"/>(aztreonam)</p></td>
<td class="bg0-br"><p class="tab">Active vs. Gram ⊖ but not Gram ⊕</p></td>
<td class="bg0-b"><p class="tab">Gram ⊖ bacterial infxn in Pt w/ PCN or Ceph allergy</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">β<b class="calibre4">-lact. inhib.</b><br class="calibre6"/>(eg, sulbactam, clavulanate)</p></td>
<td class="bg0-r"><p class="tab">Inhibit plasma-mediated β-lactamases</p></td>
<td class="bg"><p class="tab">Adds staph, <i class="calibre3">B. fragilis</i>, &amp; some GNR (<i class="calibre3">H. flu, M. cat</i>, some <i class="calibre3">E. coli</i>); intrinsic activity against <i class="calibre3">Acinetobacter</i></p></td>
</tr>
</table>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre60"/>
<col class="calibre39"/>
<col class="calibre60"/>
</colgroup>
<tr class="calibre12">
<td class="bg2-b" colspan="3"><p class="tabheadc">Cephalosporins</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b" colspan="3"><p class="tabc"><i class="calibre3">Resistant to most</i> β<i class="calibre3">-lactamases. No activity vs. enterococci.</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabhead">Gen.</p></td>
<td class="bg0-br"><p class="tabhead">Spectrum</p></td>
<td class="bg0-b"><p class="tabhead">Indications</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">1<sup class="calibre35">st</sup></b> (eg, cefazolin)</p></td>
<td class="bg0-br"><p class="tab">Most GPC (incl. staph &amp; strep, not MRSA); some GNR (incl. <i class="calibre3">E. coli, Proteus, Klebsiella</i>)</p></td>
<td class="bg0-b"><p class="tab">Used for surgical Ppx &amp; skin infxns</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">2<sup class="calibre35">nd</sup></b> (eg, cefuroxime, cefotetan)</p></td>
<td class="bg0-br"><p class="tab">↓ activity vs. GPC, ↑ vs. GNR. 2 subgroups:</p>
<p class="tab">Resp: <i class="calibre3">H. influenzae</i> &amp; <i class="calibre3">M. catarrhalis</i></p>
<p class="tab">GI/GU: ↑ activity vs. <i class="calibre3">B. fragilis</i></p></td>
<td class="bg0-b4"><p class="tab">PNA/COPD flare</p>
<p class="tab">Abdominal infxns</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">3<sup class="calibre35">rd</sup></b> (eg, ceftriaxone, ceftazidime)</p></td>
<td class="bg0-br"><p class="tab">Broad activity vs. GNR &amp; some anaerobes. Ceftazidime active vs. <i class="calibre3">Pseudomonas</i>.</p></td>
<td class="bg0-b"><p class="tab">PNA, sepsis, meningitis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">4<sup class="calibre35">th</sup></b> (eg, cefepime)</p></td>
<td class="bg0-br"><p class="tab">↑ resistance to β-lactamases (incl. of staph and <i class="calibre3">Enterobacter</i>)</p></td>
<td class="bg0-b"><p class="tab">Similar to 3<sup class="calibre35">rd</sup> gen. MonoRx for nonlocalizing febrile neutropenia</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">5<sup class="calibre35">th</sup></b> (eg, ceftaroline)</p></td>
<td class="bg0-br"><p class="tab">Only class of cephalosporin with MRSA activity. NOT active vs. <i class="calibre3">Pseudomonas</i>.</p></td>
<td class="bg0-b"><p class="tab">MRSA. Not 1<sup class="calibre35">st</sup> line for MRSA bacteremia.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Combination</b> (eg, ceftolozane-tazobactam, ceftazidime-avibactam)</p></td>
<td class="bg0-r"><p class="tab">MDR GNRs, incl. <i class="calibre3">Pseudomonas</i>. Ceftaz-avi has activity vs. some carbapenemases.</p></td>
<td class="bg"><p class="tab">Complicated UTIs, complicated intra-abdominal infections.</p></td>
</tr>
</table>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre68"/>
<col class="calibre69"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc">Other Antibiotics</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabhead">Antibiotic</p></td>
<td class="bg0-b"><p class="tabhead">Spectrum</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Vancomycin</b></p></td>
<td class="bg0-b"><p class="tab">Gram ⊕ bacteria incl. MRSA, PCNase-producing pneumococci and enterococci (except VRE)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Linezolid</b></p></td>
<td class="bg0-b2" rowspan="2"><p class="tab">GPC incl. MRSA &amp; VRE (check susceptibility for VRE)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b"><p class="tab"><b class="calibre4">Daptomycin</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Quinolones</b></p></td>
<td class="bg0-b"><p class="tab">Enteric GNR &amp; atypicals. 3<sup class="calibre35">rd</sup> &amp; 4<sup class="calibre35">th</sup> gen. ↑ activity vs. Gram ⊕.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Aminoglycosides</b></p></td>
<td class="bg0-b"><p class="tab">GNR. Synergy w/ cell-wall active abx (β-lactam, vanco) vs. GPC.<br class="calibre6"/>↓ activity in low pH (eg, abscess). No activity vs. anaerobes.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Macrolides</b></p></td>
<td class="bg0-b"><p class="tab">GPC, some respiratory Gram, atypicals</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">TMP/SMX</b></p></td>
<td class="bg0-b"><p class="tab">Some enteric GNR, <i class="calibre3">Stenotrophomonas</i>, PCP, <i class="calibre3">Nocardia, Toxo</i>, most community-acquired MRSA</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Clindamycin</b></p></td>
<td class="bg0-b"><p class="tab">Most Gram ⊕ (except enterococci) &amp; anaerobes (↑ resis. to <i class="calibre3">B. fragilis</i>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Metronidazole</b></p></td>
<td class="bg0-b"><p class="tab">Almost all anaerobic Gram, most anaerobic Gram ⊕</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Doxycycline</b></p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Rickettsia, Ehrlichia, Anaplasma, Chlamydia, Mycoplasma, Nocardia</i>, Lyme</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Tigecycline</b></p></td>
<td class="bg"><p class="tab">Many GPC incl. MRSA &amp; VRE; some GNR incl. ESBL but not <i class="calibre3">Pseudomonas</i> or <i class="calibre3">Proteus.</i></p></td>
</tr>
</table>
<p class="image1"><a id="page_11-4" class="calibre1"></a><img src="../images/00143.jpeg" alt="" class="calibre2"/></p>
<h2 class="ct"><a id="h124" class="calibre7"></a><a id="page_11-5" class="calibre7"></a><a href="part0002.html#rh138" class="calibre7">FORMULAE AND QUICK REFERENCE</a></h2>
<p class="h">C<small class="calibre30">ARDIOLOGY</small></p>
<p class="imagef"><img src="../images/00144.jpeg" alt="" class="calibre2"/></p>
<p class="fn">“Rule of 6s” for PAC: RA ≤6, RV ≤30/6, PA ≤30/12, WP ≤12. Nb 1 mmHg = 1.36 cm water or blood.</p>
<p class="h2a">Fick cardiac output</p>
<p class="noindentr">Oxygen consumption (L/min) = CO (L/min) × arteriovenous (AV) oxygen difference</p>
<p class="noindentr">CO = oxygen consumption/AV oxygen difference</p>
<p class="noindentr">Oxygen consumption must be measured (can estimate w/ 125 mL/min/m<sup class="calibre15">2</sup>, but inaccurate)</p>
<p class="noindent">AV oxygen difference = Hb (g/dL) × 10 (dL/L) × 1.36 (mL O<sub class="calibre8">2</sub>/g of Hb) × (S<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub>–S<sub class="calibre8">MV</sub>O<sub class="calibre8">2</sub>)</p>
<p class="noindent1">S<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> is measured in any arterial sample (usually 93–98%)</p>
<p class="noindent1">S<sub class="calibre8">MV</sub>O<sub class="calibre8">2</sub> (mixed venous O<sub class="calibre8">2</sub>) is measured in RA, RV, or PA (assuming no shunt) (nl ~75%)</p>
<p class="noindenttb"><img src="../images/00145.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><b class="calibre4">Assessment of RV function</b> <span class="s">(<i class="calibre3">Circ</i> 2017;136:314)</span></p>
<p class="noindent">PAPi = Pulmonary artery pulsatility index = [PA systolic – PA diastolic] / RA pressure &gt;1.0 predicts RV failure in acute MI; &lt;1.85 predicts RV failure after LVAD</p>
<p class="h2a"><b class="calibre4">Shunts</b></p>
<p class="noindenttb"><img src="../images/00146.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><b class="calibre4">Valve equations</b></p>
<p class="noindent">Simplified Bernoulli: Pressure gradient (∇P) = 4 × v<sup class="calibre15">2</sup> (where v = peak flow velocity)</p>
<p class="noindent">Continuity (conservation of flow): Area<sub class="calibre8">1</sub> × Velocity<sub class="calibre8">1</sub> = A<sub class="calibre8">2</sub> × V<sub class="calibre8">2</sub> (where 1 &amp; 2 different points)</p>
<p class="noindenttb"><img src="../images/00147.jpeg" alt="" class="calibre2"/></p>
<p class="noindenttb"><a id="page_11-6" class="calibre1"></a><img src="../images/00148.jpeg" alt="" class="calibre2"/></p>
<p class="h">P<small class="calibre30">ULMONARY</small></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre16"/>
<col class="calibre26"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc">Chest Imaging (CXR &amp; CT) Patterns</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabhead">Pattern</p></td>
<td class="bg0-br"><p class="tabheadc">Pathophysiology</p></td>
<td class="bg0-b"><p class="tabheadc">Ddx</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Consolidation</p></td>
<td class="bg0-br"><p class="tab">Radiopaque material in air space &amp; interstitium patent airway → “air bronchograms”</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Acute:</i> water <b class="calibre4">(pulm edema)</b>, pus <b class="calibre4">(PNA)</b>, <b class="calibre4">blood</b></p>
<p class="tabh"><i class="calibre3">Chronic:</i> neoplasm (BAC, lymphoma), aspiration, inflammatory (COP, eosinophilic PNA), PAP, granuloma (TB/fungal, alveolar sarcoid)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Ground glass (CT easier than CXR)</p></td>
<td class="bg0-br"><p class="tab">Interstitial thickening or partial filling of alveoli (but vessels visible)</p></td>
<td class="bg0-b"><p class="tabh"><i class="calibre3">Acute:</i> pulm edema, infxn (PCP, viral, resolving bact. PNA)</p>
<p class="tab"><i class="calibre3">Chronic:</i> ILD</p>
<p class="tabh">w/o fibrosis: acute hypersens., DIP/RB, PAP w/ fibrosis: IPF</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Septal lines Kerley A &amp; B</p></td>
<td class="bg0-br"><p class="tab">Radiopaque material in septae</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Cardiogenic pulm edema</b>, interstitial PNA viral, mycoplasma, lymphangitic tumor</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Reticular</p></td>
<td class="bg0-br"><p class="tab">Lace-like net (ILD)</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">ILD</b> (esp. IPF, CVD, bleomycin, asbestos)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Nodules</p></td>
<td class="bg0-br"><p class="tab">Tumor</p>
<p class="tab">Granulomas</p>
<p class="tab">Abscess</p></td>
<td class="bg0-b"><p class="tabh"><i class="calibre3">Cavitary:</i> <b class="calibre4">Primary or metastatic cancer</b>, <b class="calibre4">TB</b> (react. or miliary), <b class="calibre4">fungus</b>, Wegener’s, RA <b class="calibre4">septic emboli</b>, PNA</p>
<p class="tabh"><i class="calibre3">Noncavitary:</i> any of above + <b class="calibre4">sarcoid</b>, hypersens. pneum., HIV, Kaposi’s sarcoma</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Wedge opac.</p></td>
<td class="bg0-br"><p class="tab">Peripheral infarct</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">PE</b>, cocaine, angioinv. aspergillus, Wegener’s</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Tree-in-bud (best on CT)</p></td>
<td class="bg0-br"><p class="tab">Inflammation of small airways</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Bronchopneumonia</b>, endobronchial TB/MAI, viral PNA, aspiration, ABPA, CF, asthma, COP</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Hilar fullness</p></td>
<td class="bg0-br"><p class="tab">↑ LN or pulm arteries</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Neoplasm</b> (lung, mets, lymphoma)</p>
<p class="tab"><b class="calibre4">Infxn</b> (AIDS); <b class="calibre4">Granuloma</b> (sarcoid/TB/fungal)</p>
<p class="tab">Pulmonary hypertension</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Upper lobe</p></td>
<td class="bg0-br"><p class="tab">n/a</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">TB</b>, fungal, sarcoid, hypersens. pneum., CF, XRT</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Lower lobe</p></td>
<td class="bg0-br"><p class="tab">n/a</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Aspiration</b>, bronchiect., IPF, RA, SLE, asbestos</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Peripheral</p></td>
<td class="bg0-r"><p class="tab">n/a</p></td>
<td class="bg"><p class="tab">COP, IPF &amp; DIP, eos PNA, asbestosis</p></td>
</tr>
</table>
<p class="h2a"><b class="calibre4">CXR in heart failure</b></p>
<p class="bl"><span class="sbl">•</span> ↑ cardiac silhouette (in systolic dysfxn, not in diastolic)</p>
<p class="bl"><span class="sbl">•</span> Pulmonary venous hypertension: cephalization of vessels (vessels size &gt; bronchi in upper lobes), peribronchial cuffing (fluid around bronchi seen on end → small circles), Kerley B lines (horizontal 1–2-cm lines at bases), ↑ vascular pedicle width, loss of sharp vascular margins, pleural effusions (~75% bilateral)</p>
<p class="bl"><span class="sbl">•</span> Pulmonary edema: ranges from ground glass to consolidation; often dependent and central, sparing outer third (“bat wing” appearance)</p>
<p class="noindent"><b class="calibre4">Dead space</b> = lung units that are ventilated but not perfused</p>
<p class="noindent"><b class="calibre4">Intrapulmonary shunt</b> = lung units that are perfused but not ventilated</p>
<p class="noindenttb"><img src="../images/00149.jpeg" alt="" class="calibre2"/></p>
<p class="noindent"><b class="calibre4">A-a gradient</b> = P<sub class="calibre8">A</sub>O<sub class="calibre8">2</sub> – P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> [normal A-a gradient ≈ 4 + (age/4)]</p>
<p class="noindent"><b class="calibre4">Minute ventilation</b> (V<sub class="calibre8">E</sub>) = tidal volume (V<sub class="calibre8">T</sub>) × respiratory rate (RR)(nl 4–6 L/min)</p>
<p class="noindent"><b class="calibre4">Tidal volume</b> (V<sub class="calibre8">T</sub>) = alveolar space (V<sub class="calibre8">A</sub>) + dead space (V<sub class="calibre8">D</sub>)</p>
<p class="noindenttb"><img src="../images/00150.jpeg" alt="" class="calibre2"/></p>
<p class="h"><a id="page_11-7" class="calibre7"></a>G<small class="calibre30">ASTROENTEROLOGY</small></p>
<p class="image1"><img src="../images/00151.jpeg" alt="" class="calibre2"/></p>
<p class="h">N<small class="calibre30">EPHROLOGY</small></p>
<p class="noindent"><b class="calibre4">Anion gap</b> (AG) = Na – (Cl + HCO<sub class="calibre8">3</sub>) (normal = [alb] × 2.5; typically 12 ± 2 mEq)</p>
<p class="noindent"><b class="calibre4">Delta-delta</b> (ΔΔ) = [Δ AG (ie, calc. AG – expected) / Δ HCO<sub class="calibre8">3</sub> (ie, 24 – measured HCO<sub class="calibre8">3</sub>)]</p>
<p class="noindent"><b class="calibre4">Urine anion gap</b> (UAG) = (UN<sub class="calibre8">a</sub> + U<sub class="calibre8">K</sub>) – U<sub class="calibre8">Cl</sub></p>
<p class="noindent"><img src="../images/00152.jpeg" alt="" class="calibre2"/></p>
<p class="noindent">However, Δ in Na depends on glc <span class="s">(<i class="calibre3">Am J Med</i> 1999;106:399)</span></p>
<p class="noindent">Δ is 1.6 mEq per each 100 mg/dL ↑ in glc ranging from 100–440</p>
<p class="noindent">Δ is 4 mEq per each 100 mg/dL ↑ in glc beyond 440</p>
<p class="noindentr"><b class="calibre4">Total body water</b> (TBW) = 0.60 × IBW (× 0.85 if female and × 0.85 if elderly)</p>
<p class="noindentr"><img src="../images/00153.jpeg" alt="" class="calibre2"/></p>
<p class="noindentr"><b class="calibre4">Trans-tubular potassium gradient</b> (TTKG) = [U<sub class="calibre8">K</sub> / P<sub class="calibre8">K</sub>] / [U<sub class="calibre8">Osm</sub> / P<sub class="calibre8">Osm</sub>]</p>
<p class="h">H<small class="calibre30">EMATOLOGY</small></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre70"/>
<col class="calibre72"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc">Peripheral Smear Findings <span class="s2">(also see Photo Inserts)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabhead">Feature</p></td>
<td class="bg0-b"><p class="tabhead">Abnormalities and Diagnoses</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Size</b></p></td>
<td class="bg0-b"><p class="tab">normocytic vs. microcytic vs. macrocytic → see below</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Shape</b></p></td>
<td class="bg0-b"><p class="tabh"><b class="calibre4">Anisocytosis</b> → unequal RBC size; <b class="calibre4">poikilocytosis</b> → irregular RBC shape acanthocytes = <b class="calibre4">spur</b> cells (irregular sharp projections) → liver disease</p>
<p class="tabh"><b class="calibre4">Bite</b> cells (removal of Heinz bodies by phagocytes) → G6PD deficiency echinocytes = <b class="calibre4">burr</b> cells (even, regular projections) → uremia, artifact</p>
<p class="tab"><b class="calibre4">Pencil cell</b> → long, thin, hypochromic - very common in adv. iron deficiency</p>
<p class="tab"><b class="calibre4">Rouleaux</b> → hyperglobulinemia (eg, multiple myeloma)</p>
<p class="tab"><b class="calibre4">Schistocytes</b>, helmet cells → MAHA (eg, DIC, TTP/HUS), mechanical valve</p>
<p class="tab"><b class="calibre4">Spherocytes</b> → HS, AIHA; <b class="calibre4">sickle</b> cells → sickle cell anemia</p>
<p class="tab"><b class="calibre4">Stomatocyte</b> → central pallor appears as curved slit → liver disease, EtOH</p>
<p class="tab"><b class="calibre4">Target</b> cells → liver disease, hemoglobinopathies, splenectomy</p>
<p class="tabh"><b class="calibre4">Tear drop</b> cells = dacryocytes → myelofibrosis, myelophthisic anemia, megaloblastic anemia, thalassemia</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><a id="page_11-8" class="calibre1"></a><p class="tab"><b class="calibre4">Intra- RBC findings</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Basophilic stippling</b> (ribosomes) → abnl Hb, sideroblastic, megaloblastic</p>
<p class="tab"><b class="calibre4">Heinz bodies</b> (denatured Hb) → G6PD deficiency, thalassemia</p>
<p class="tabh"><b class="calibre4">Howell-Jolly bodies</b> (nuclear fragments) → splenectomy or functional asplenia (eg, advanced sickle cell)</p>
<p class="tab"><b class="calibre4">Nucleated</b> RBCs → hemolysis, extramedullary hematopoiesis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">WBC findings</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Blasts</b> → leukemia, lymphoma; <b class="calibre4">Auer rods</b> → acute myelogenous leukemia</p>
<p class="tab"><b class="calibre4">Hypersegmented</b> (&gt;5 lobes) PMNs: megaloblastic anemia (B<sub class="calibre13">12</sub>/folate def.)</p>
<p class="tab"><b class="calibre4">Pseudo-Pelger-Huët anomaly</b> (bilobed nucleus, “pince-nez”) → MDS</p>
<p class="tabh"><b class="calibre4">Toxic granules</b> (coarse, dark blue) and <b class="calibre4">Döhle bodies</b> (blue patches of dilated endoplasmic reticulum) → (sepsis, severe inflammation)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Platelet</b></p></td>
<td class="bg"><p class="tab"><b class="calibre4">Clumping</b> → artifact, repeat plt count</p>
<p class="tab"><b class="calibre4">#</b> → periph blood plt count ~10,000 plt for every 1 plt seen at hpf (100×)</p>
<p class="tab"><b class="calibre4">Size</b> → MPV (mean platelet volume) enlarged in ITP</p></td>
</tr>
</table>
<p class="tsr">(<i class="calibre3">NEJM</i> 2005;353:498)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre61"/>
<col class="calibre73"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc">Heparin for Thromboembolism</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b" colspan="2"><p class="tabc">80 U/kg bolus</p>
<p class="tabc">18 U/kg/h</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabheadc">PTT</p></td>
<td class="bg0-b"><p class="tabheadc">Adjustment</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">&lt;40</p></td>
<td class="bg0-b"><p class="tabc">bolus 5000 U, ↑ rate 300 U/h</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">40–49</p></td>
<td class="bg0-b"><p class="tabc">bolus 3000 U, ↑ rate 200 U/h</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">50–59</p></td>
<td class="bg0-b"><p class="tabc">↑ rate 150 U/h</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">60–85</p></td>
<td class="bg0-b"><p class="tabc">no Δ</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">86–95</p></td>
<td class="bg0-b"><p class="tabc">↓ rate 100 U/h</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">96–120</p></td>
<td class="bg0-b"><p class="tabc">hold 30 min, ↓ rate 100 U/h</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">&gt;120</p></td>
<td class="bg"><p class="tabc">hold 60 min, ↓ rate 150 U/h</p></td>
</tr>
</table>
<p class="tsr">(Modified from <i class="calibre3">Chest</i> 2008;133:141S)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre61"/>
<col class="calibre73"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc">Heparin for ACS</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b" colspan="2"><p class="tabc">60 U/kg bolus (max 4000 U)</p>
<p class="tabc">12 U/kg/h (max 1000 U/h)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabheadc">PTT</p></td>
<td class="bg0-b"><p class="tabheadc">Adjustment</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">&lt;40</p></td>
<td class="bg0-b"><p class="tabc">bolus 3000 U, ↑ rate 100 U/h</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">40–49</p></td>
<td class="bg0-b"><p class="tabc">↑ rate 100 U/h</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">50–75</p></td>
<td class="bg0-b"><p class="tabc">no Δ</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">76–85</p></td>
<td class="bg0-b"><p class="tabc">↓ rate 100 U/h</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">86–100</p></td>
<td class="bg0-b"><p class="tabc">hold 30 min, ↓ rate 100 U/h</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tabc">&gt;100</p></td>
<td class="bg"><p class="tabc">hold 60 min, ↓ rate 200 U/h</p></td>
</tr>
</table>
<p class="tsr">(Modified from <i class="calibre3">Circ</i> 2007;116:e148 &amp; <i class="calibre3">Chest</i> 2008;133:670)</p>
<p class="noindent">✔ PTT q6h after every Δ (t<sub class="calibre8">½</sub> of heparin ~90 min) and then qd or bid once PTT is therapeutic</p>
<p class="noindent">✔ CBC qd (to ensure Hct and plt counts are stable)</p>
<p class="imagef"><img src="../images/00154.jpeg" alt="" class="calibre2"/></p>
<p class="fn">(<i class="calibre3">Annals</i> 1997;126:133; <i class="calibre3">Archives</i> 1999;159:46) or, go to <a href="http://www.warfarindosing.org" class="calibre1">www.warfarindosing.org</a></p>
<p class="h2a"><b class="calibre4">Warfarin-heparin overlap therapy</b></p>
<p class="bl"><span class="sbl">•</span> Indications: when failure to anticoagulate carries ↑ risk of morbidity or mortality (eg, DVT/PE, intracardiac thrombus)</p>
<p class="bl"><span class="sbl">•</span> Rationale: (1) Half-life of factor VII (3–6 h) is shorter than half-life of factor II (60–72 h);</p>
<p class="bl5">∴ warfarin can elevate PT <i class="calibre3">before achieving a true antithrombotic state</i></p>
<p class="bl5">(2) Protein C also has half-life less than that of factor II;</p>
<p class="bl5">∴ theoretical concern of <i class="calibre3">hypercoagulable state</i> before antithrombotic state</p>
<p class="bl"><span class="sbl">•</span> Method: (1) Therapeutic PTT is achieved using heparin</p>
<p class="bl5">(2) Warfarin therapy is initiated</p>
<p class="bl5">(3) Heparin continued until INR therapeutic for ≥2 d and ≥4–5 d of warfarin (roughly corresponds to ~2 half-lives of factor II or a reduction to ~25%)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc">Common Warfarin-Drug Interactions</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabheadc">Drugs that ↑ PT</p></td>
<td class="bg0-b"><p class="tabheadc">Drugs that ↓ PT</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Amiodarone</p>
<p class="tabh">Antimicrobials: erythromycin, ? clarithro, ciprofloxacin, MNZ, sulfonamides</p>
<p class="tab">Antifungals: azoles</p>
<p class="tab">Acetaminophen, cimetidine, levothyroxine</p></td>
<td class="bg"><p class="tab">Antimicrobials: rifampin</p>
<p class="tabh">CNS: barbiturates, carbamazepine, phenytoin (initial transient ↑ PT)</p>
<p class="tab">Cholestyramine</p></td>
</tr>
</table>
<p class="h">E<small class="calibre30">NDOCRINOLOGY</small></p>
<p class="imagef"><img src="../images/00155.jpeg" alt="" class="calibre2"/></p>
<p class="image"><a id="page_11-9" class="calibre1"></a><img src="../images/00156.jpeg" alt="" class="calibre2"/></p>
<p class="h">N<small class="calibre30">EUROLOGY</small></p>
<p class="image1"><img src="../images/00157.jpeg" alt="" class="calibre2"/></p>
<p class="h">O<small class="calibre30">THER</small></p>
<p class="noindent"><img src="../images/00158.jpeg" alt="" class="calibre2"/></p>
<h2 class="ct"><a id="page_11-10" class="calibre7"></a>NOTES</h2>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../k34gmbu8.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-74951b69f9a94472af57c47504abb1f1">Title Page</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-74951b69f9a94472af57c47504abb1f1">Copyright Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-74951b69f9a94472af57c47504abb1f1">Contents</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-74951b69f9a94472af57c47504abb1f1">Contributing Authors</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-74951b69f9a94472af57c47504abb1f1">Foreword</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-74951b69f9a94472af57c47504abb1f1">Preface</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-74951b69f9a94472af57c47504abb1f1">Cardiology</a>
      <ul>
        <li>
          <a href="part0006.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0006.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0006.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0006.html#h4">Coronary Angiography and Revascularization</a>
        </li>
        <li>
          <a href="part0006.html#h5">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h6">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0006.html#h7">Heart Failure</a>
        </li>
        <li>
          <a href="part0006.html#h8">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0006.html#h9">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0006.html#h10">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0006.html#h11">Hypertension</a>
        </li>
        <li>
          <a href="part0006.html#h12">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0006.html#h13">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h14">Arrhythmias</a>
        </li>
        <li>
          <a href="part0006.html#h15">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0006.html#h16">Syncope</a>
        </li>
        <li>
          <a href="part0006.html#h17">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0006.html#h18">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0006.html#h19">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0007.html#6LJU0-74951b69f9a94472af57c47504abb1f1">Pulmonary</a>
      <ul>
        <li>
          <a href="part0007.html#h20">Dyspnea</a>
        </li>
        <li>
          <a href="part0007.html#h21">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0007.html#h22">Asthma</a>
        </li>
        <li>
          <a href="part0007.html#h23">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0007.html#h24">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0007.html#h25">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0007.html#h26">Hemoptysis</a>
        </li>
        <li>
          <a href="part0007.html#h27">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0007.html#h28">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0007.html#h29">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0007.html#h30">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0007.html#h31">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0007.html#h32">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h33">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0007.html#h34">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0007.html#h35">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0007.html#h36">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0007.html#h37">Toxicology</a>
        </li>
        <li>
          <a href="part0007.html#h38">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-74951b69f9a94472af57c47504abb1f1">Gastroenterology</a>
      <ul>
        <li>
          <a href="part0008.html#h39">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0008.html#h40">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0008.html#h41">Diarrhea</a>
        </li>
        <li>
          <a href="part0008.html#h42">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0008.html#h43">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0008.html#h44">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0008.html#h45">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0008.html#h46">Pancreatitis</a>
        </li>
        <li>
          <a href="part0008.html#h47">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0008.html#h48">Hepatitis</a>
        </li>
        <li>
          <a href="part0008.html#h49">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0008.html#h50">Cirrhosis</a>
        </li>
        <li>
          <a href="part0008.html#h51">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0008.html#h52">Ascites</a>
        </li>
        <li>
          <a href="part0008.html#h53">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-74951b69f9a94472af57c47504abb1f1">Nephrology</a>
      <ul>
        <li>
          <a href="part0009.html#h54">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0009.html#h55">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h56">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h57">Renal Failure</a>
        </li>
        <li>
          <a href="part0009.html#h58">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h59">Urinalysis</a>
        </li>
        <li>
          <a href="part0009.html#h60">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-74951b69f9a94472af57c47504abb1f1">Hematology-Oncology</a>
      <ul>
        <li>
          <a href="part0010.html#h61">Anemia</a>
        </li>
        <li>
          <a href="part0010.html#h62">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0010.html#h63">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0010.html#h64">Coagulopathies</a>
        </li>
        <li>
          <a href="part0010.html#h65">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0010.html#h66">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0010.html#h67">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0010.html#h68">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0010.html#h69">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0010.html#h70">Leukemia</a>
        </li>
        <li>
          <a href="part0010.html#h71">Lymphoma</a>
        </li>
        <li>
          <a href="part0010.html#h72">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0010.html#h73">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0010.html#h74">Lung Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h75">Breast Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h76">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h77">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h78">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0010.html#h79">Hepatocellular Carcinoma (HCC)</a>
        </li>
        <li>
          <a href="part0010.html#h80">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0010.html#h81">Chemotherapy &amp; Immunotherapy Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-74951b69f9a94472af57c47504abb1f1">Infectious Diseases</a>
      <ul>
        <li>
          <a href="part0011.html#h82">Pneumonia</a>
        </li>
        <li>
          <a href="part0011.html#h83">Fungal Infections</a>
        </li>
        <li>
          <a href="part0011.html#h84">Infections in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0011.html#h85">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0011.html#h86">Soft Tissue and Bone Infections</a>
        </li>
        <li>
          <a href="part0011.html#h87">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0011.html#h88">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0011.html#h89">Tuberculosis</a>
        </li>
        <li>
          <a href="part0011.html#h90">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0011.html#h91">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0011.html#h92">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-74951b69f9a94472af57c47504abb1f1">Endocrinology</a>
      <ul>
        <li>
          <a href="part0012.html#h93">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h94">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h95">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h96">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h97">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0012.html#h98">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-74951b69f9a94472af57c47504abb1f1">Rheumatology</a>
      <ul>
        <li>
          <a href="part0013.html#h99">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0013.html#h100">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0013.html#h101">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0013.html#h102">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0013.html#h103">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0013.html#h104">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0013.html#h105">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0013.html#h106">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0013.html#h107">Vasculitis</a>
        </li>
        <li>
          <a href="part0013.html#h108">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0013.html#h109">Cryoglobulinemia</a>
        </li>
        <li>
          <a href="part0013.html#h110">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-74951b69f9a94472af57c47504abb1f1">Neurology</a>
      <ul>
        <li>
          <a href="part0014.html#h111">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0014.html#h112">Seizures</a>
        </li>
        <li>
          <a href="part0014.html#h113">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0014.html#h114">Dizziness</a>
        </li>
        <li>
          <a href="part0014.html#h115">Stroke</a>
        </li>
        <li>
          <a href="part0014.html#h116">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0014.html#h117">Headache</a>
        </li>
        <li>
          <a href="part0014.html#h118">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-74951b69f9a94472af57c47504abb1f1">Consults</a>
      <ul>
        <li>
          <a href="part0015.html#h119">Surgical Issues</a>
        </li>
        <li>
          <a href="part0015.html#h120">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0015.html#h121">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-74951b69f9a94472af57c47504abb1f1">Appendix</a>
      <ul>
        <li>
          <a href="part0016.html#h122">ICU Medications &amp; Treatment of Hypotension/Shock</a>
        </li>
        <li>
          <a href="part0016.html#h123">Antibiotics</a>
        </li>
        <li>
          <a href="part0016.html#h124">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-74951b69f9a94472af57c47504abb1f1">Abbreviations</a>
    </li>
    <li>
      <a href="part0018.html#H5A40-74951b69f9a94472af57c47504abb1f1">Index</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-74951b69f9a94472af57c47504abb1f1">Photo Inserts</a>
      <ul>
        <li>
          <a href="part0019.html#h125">Radiology</a>
        </li>
        <li>
          <a href="part0019.html#h126">Echocardiography &amp; Coronary Angiography</a>
        </li>
        <li>
          <a href="part0019.html#h127">Peripheral Blood Smears &amp; Leukemias</a>
        </li>
        <li>
          <a href="part0019.html#h128">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0022.html#KVCC0-74951b69f9a94472af57c47504abb1f1">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0015.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../k34gmbu8.html" class="calibreAHome">start
</a>

    
      <a href="part0017.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
